*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
ICD Code | ICD Description | Total National Projected Hospitalizations - Annualized (Present on Admission - All) | Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | Total Medicare Hospitalization after Exclusion | Avg. LOS | Readmission Rate (%) | Unplanned Readmission Rate (%) | Total Medicare Payments | Payment Per Day | Payment Per Hospitalization | Total Medicare Charges | Avg. Charges | Mortality Rate (%) | SNF Discharge Rate (%) | Home Discharge Rate (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
E2609 | Other primary hyperaldosteronism | 11.76 | |||||||||||||
E2601 | Conn's syndrome | NA |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
ICD Code | ICD Description | Total National Projected Hospitalizations - Annualized (Present on Admission - All) | Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | Total Medicare Hospitalization after Exclusion | Avg. LOS | Readmission Rate (%) | Unplanned Readmission Rate (%) | Total Medicare Payments | Payment Per Day | Payment Per Hospitalization | Total Medicare Charges | Avg. Charges | Mortality Rate (%) | SNF Discharge Rate (%) | Home Discharge Rate (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
E2609 | Other primary hyperaldosteronism | 5.31 | 21.24 | ||||||||||||||||
E2601 | Conn's syndrome | 5.71 | 21.71 | ||||||||||||||||
E2602 | Glucocorticoid-remediable aldosteronism | 5.27 | NA |